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Abstract
The principal goal of this project was to take synthetic boron containing compounds from
their academic research to the applied research phase. Adequate boron-containing biomolecules
were synthesized and characterized as new possible medical treatments of glioblastomas. The
boron neutron capture therapy (BNCT) is a promising new and effective form of cancer
treatment.
Although the main objective of the project was to synthesize boron-containing
biomolecules and carborane cage compounds with various organic moieties attached for
therapeutic applications and to explore separate procedures for the development of new medical
treatment options, the immediate objective was to synthesize biocompatible molecules that could
be used as carrier molecules for boron neutron capture therapy in medical applications. In the
future, the carborane cage’s will be functionalized with cancer cell receptors such as folic acid,
glucose, or cancer recepting sites. Eventually, further biological analysis will have to be
conducted on all synthesized molecules.

Introduction
According to the National Brain Tumor Society, “An estimated 700,000 people in the
United States are living with a primary brain tumor, and approximately 85,000 more will be
diagnosed in 2021”. Of the 700,000 people, about 30% are malignant meaning that they are
cancerous. The most common symptoms of malignant brain tumors include headaches, nausea,
vomiting, vision problems, gradual loss of sensation or movement in arms or legs, and
personality changes. As of now, treatment options include surgery, radiation, and chemotherapy.
Cancer is a devastating disease, with our boron research, we plan on finding an

alternative treatment option that doesn't come with debilitating side effects for the patients.
Boron Neutron Capture Therapy (BNCT) is a binary treatment of cancer where a B-10
containing compound is selectively delivered to the tumor tissues before irradiation by neutrons.
The B-10 isotope is preferred as it is the most naturally abundant isotope. There is an interaction
with the boron-10 atoms and the thermal neutron produces an ɑ-particle as a result of the
irradiation with thermal neutrons. The linear energy transfer of the heavily charged Li-7 ion and
low energy gamma rays have a diameter range of one cell that reduce the effect on the
surrounding tissue because the radiant energy is limited to the cell from which they appear
(Figure 1).

Figure 1. Boron neutron capture reaction : Emission of 1.47MeV α-particle, 0.84 MeV Liparticle, and 0.48 MeV γ-ray.

The minimal effect of the regions that don't contain boron can still be achieved when the
targeted region is dosed with neutrons that are fluctuating in size. This is because the cross
section of boron for neutrons is three orders of magnitude larger than the nuclei found in living
tissue. The necessary boron concentration is estimated to be 35 µg per gram of tissue or 10⁹
10

B atoms per cell. It is essential that the surrounding tissues contain less than 5 µg of boron-

10 per gram of tissue to prevent damage to those healthy tissues. If the boron is transported in
adequate specificity and quantities with the aid of tumor selective agents, then the death of the
tumor cells will be successful. There are currently two compounds sodium borocaptate (BSH)
and boronophenylalanine (BPA) available for clinical trials, but they only target malignant brain
tumors (Figure 2).

Figure 2: Boron Compounds Currently Used in Clinical Trials, BPA on the left and BSH on the
right

Methodology
This capstone project is quantitative and includes a mix of primary and secondary
sources. Each reaction performed included the use of various laboratory equipment such as a
round bottom flask, test tubes, magnetic stir bar, TLC plate, iodine stain, ninhydrin stain,
separatory funnel, silica-gel column, and a rotary evaporator. There was a total of four steps per
reaction, one reaction was conducted with cesium carbonate (Cs₂CO₃) as a base while the other

reaction utilized potassium carbonate (K₂CO₃) as the base. The two different bases are being
tested and compared to determine which base resulted in a higher yield.
Substitution reaction.
A substitution reaction was first placed by dissolving 2’,7’-dichlorofluorescein in
dimethylformamide (DMF) in a round bottom flask. Once the 2’,7’-dichlorofluorescein was fully
dissolved, potassium carbonate (K₂CO₃) was then added to the reaction to deprotonate the
alcohol group and the reaction was left to spin for about 3 minutes. The deprotonation of the
alcohol group was necessary to aid in the attachment of propargyl bromide. Next, the round
bottom flask was then covered with aluminum foil as the reaction is light sensitive and 0.5 mL of
propargyl bromide was then added and the reaction was left to spin overnight at 90℃ in an oil
bath to ensure the reaction was heated evenly. The following day, the reaction was analyzed
through thin layer chromatography with hexane and ethyl acetate to ensure the reaction was
complete. An extraction was then conducted with deionized water and ethyl acetate and the
organic layer was dried over sodium sulfate. A silica gel column chromatography was then done
to purify the product and nuclear magnetic resonance (NMR) was then done to confirm the
presence of the desired product. The scheme for the substitution reaction can be seen in Figure 3
below.

Figure 3: 2’,7’-dichlorofluorescein substitution reaction with potassium carbonate (K₂CO₃) and
cesium carbonate (Cs₂CO₃).

The same reaction was then conducted with cesium carbonate (Cs₂CO₃) to analyze which of the
two bases would result in a better yield. After analysis it was determined that the reaction
utilizing potassium carbonate (K₂CO₃) as a base resulted in a higher yield.
Dehydration Reaction.
After the propargyl bromide was successfully attached to the 2’,7’-dichlorofluorescein, a
dehydration reaction was conducted. The product synthesized using the potassium carbonate
(K₂CO₃) base was dissolved in methanol in a round bottom flask. Hydrazine (NH₂-NH₂) was then
added to the reaction so it could open the carbon ring and replace the oxygen with a nitrogen
bonded amino group prior to closing the ring again. The reaction was left to spin overnight in an
80℃ oil bath to ensure the heat was evenly distributed and an extraction was done the following
day with deionized water and ethyl acetate. The organic layer was then collected and dried over
sodium sulfate. The product was then characterized through nuclear magnetic resonance (NMR)
to confirm the presence of the desired product. The scheme of the dehydration reaction can be
seen below.

Figure 4: 2’,7’-dichlorofluorescein dehydration reaction with hydrazine on the previously
synthesized potassium carbonate (K₂CO₃) and cesium carbonate (Cs₂CO₃) products.
Once again the same reaction was placed for with cesium carbonate (Cs₂CO₃) and the reaction
with potassium carbonate (K₂CO₃) resulted in a higher yield.
Esterification reaction.

To begin the esterification reaction, carboxy phenyl boronic acid (HO2CC6H4B(OH)2 was
dissolved in dimethylformamide (DMF) in a round bottom flask. Once the carboxy phenyl
boronic acid was dissolved, 4-dimethylaminopyridine was then added to the reaction and the
reaction was left to spin on a magnetic stirring hot plate for about 10 minutes. The round bottom
flask was then placed in ice to ensure the cold temperature was maintained throughout the
addition of 1-ethyl-3-3-dimethylaminopropyl carbodiimide (EDC) to allow it enough time to
react. The reaction was left to spin for at least 30 minutes. While the reaction was spinning, the
protected 2’,7’-dichlorofluorescein product was then dissolved in dimethylformamide and was
then added to the reaction and left to spin overnight in an oil bath at 80℃. The following day
thin layer chromatography (TLC) was then done to ensure the reaction was completed and an
extraction was then done with deionized water and ethyl acetate. The organic layer was then
dried with sodium sulfate and the product was further purified using a silica gel column
chromatography technique. Nuclear magnetic resonance (NMR) was then done to confirm the
desired product had indeed been obtained. The scheme of the esterification reaction can be seen
below in Figure 5.

Figure 5: Esterification reaction on 2’,7’-dichlorofluorescein with protected carboxy phenyl
boronic acid.
The esterification reaction was conducted with a protected carboxy phenyl boronic acid as well
as an unprotected boronic acid. This was done because when using an unprotected boronic acid,
the hydroxyl groups will be reactive with any base which will result in a negative charge on the
hydroxyl groups and will then lead to the breaking of the carborane cage in future synthesis.

Cage Closing Reaction.
The final reaction conducted was a cage closing reaction. The 2’,7’-dichlorofluorescein
propargyl bromide was reacted with decaborane and dissolved in anhydrous toluene and
acetonitrile. The reaction was then left to spin at 111℃ as that was roughly toluene’s boiling
point and it was important to ensure the maximum boiling point was reached. The reaction was
then analyzed through thin layer chromatography (TLC) to ensure the reaction was completed
with pure dichloromethane (DCM) and the reaction was then extracted with deionized water and
ethyl acetate. The organic layer was then dried over sodium sulfate and the product was further
purified through a silica gel column chromatography technique. Further characterization of the
product was done through nuclear magnetic resonance (NMR) to ensure that the desired product
was obtained. The scheme for the cage closing reaction can be seen in Figure 6.

Figure 6: Cage closing reaction with 2’,7’-dichlorofluorescein carborane complex
Further characterization of the product was done through nuclear magnetic resonance (NMR) to
ensure that the desired product was obtained.
Results
Potassium carbonate (K₂CO₃) and cesium carbonate (Cs₂CO₃) were both tested to
determine which of the two bases would result in a higher yield. Based on the synthesis of the
substitution reaction, the potassium carbonate (K₂CO₃) reaction resulted in a successful synthesis
but will have to be further optimized to obtain a higher yield.

The product was then further characterized through proton nuclear magnetic resonance (NMR)
and the spectrum can be seen in Figure 7 below.

Figure 7: Proton NMR spectrum for the substitution reaction with potassium carbonate and
propargyl bromide.
An estimated literature value is given at 3.37 ppm, based on the obtained spectrum there is a
peak at 3.509 ppm which represents the triple bond in the propargyl bromide complex. There is
also a peak seen at around 4.8 ppm which represent the carbons where the propargyl bromide
attached to the 2’,7’-dichlorofluorescein. The dehydration reaction for both the cesium carbonate
(Cs₂CO₃) and potassium carbonate (K₂CO₃) reactions were then conducted and the potassium
carbonate (K₂CO₃) reaction with hydrazine (NH₂-NH₂) resulted in a higher yield. The
characterization of the potassium carbonate (K₂CO₃) product from proton nuclear magnetic
resonance can be seen in Figure 8.

Figure 8 : Proton NMR spectrum for the dehydration reaction for the 2’,7’-dichlorofluorescein
complex.
As seen in the spectrum above (Figure 8), it can be seen that once again there is an estimated
value of about 3.37 ppm for the triple bond of the propargyl bromide complex which is seen at
3.503 ppm in the spectrum. The hydrazine complex can be represented by the two hydrogens at
about 5.3-5.4 ppm which represents the product. The esterification reaction was then conducted
and the percent yield for the protected carboxy phenyl boronic acid was then compared to the
one obtained for the unprotected carboxy phenyl boronic acid, because of the synthesis, the
protected carboxy phenyl boronic acid resulted in a higher yield. Although it resulted in a higher
yield, further optimization of the product was necessary. The product was then further analyzed
through proton nuclear magnetic resonance and the spectrum can be seen in Figure 9.

Figure 9: Boron NMR for the cage closing reaction for 2’,7’-dichlorofluorescein
In Figure 9, there is a peak at about 4.1 ppm which represents the hydrogens from the hydroxyl
groups in the boronic acid. Also, because this was the final step of the synthesis of the 2’,7’dichlorofluorescein carborane complex, the final product was further characterized through
boron nuclear magnetic resonance (NMR) which is pictured below.

Figure 11: Boron NMR for the cage closing reaction for 2’,7’-dichlorofluorescein

The boron nuclear magnetic resonance (NMR) spectrum (Figure 11) determined that the ideal
number of peaks for a closed carborane 2’,7’-dichlorofluorescein cage complex were obtained.

Discussion
Based on the results obtained throughout this research project on Boron Biomolecules
for Medical Applications, all of the reactions have been successfully synthesized and have been
characterized with proton, carbon, and boron NMR. Some of the reactions were in the process of
being further analyzed through mass spectrometry but due to some challenges with funding the
analysis have not been completed at this moment. At first the cesium carbonate base was used to
synthesize the substitution reaction and later the base was switched to potassium carbonate to
determine which of the two bases would result in a higher yield. Based on the obtained results,
the potassium carbonate reaction had a higher yield which could be due to the fact that cesium

carbonate is generally used for sensitive reactions and requires a sensible base strength. As for
the esterification reaction, two reactions were conducted. One was with a protected carboxy
phenyl boronic acid and the other was with an unprotected carboxy phenyl boronic acid. The
purpose of testing both was to optimize the reaction and determine which of the two would result
in a higher yield. The protected carboxy phenyl boronic acid resulted in a higher yield which
could be due to the fact that the unprotected boronic acid is much less stable and sometimes
when reacted with certain bases, the hydroxyl groups will react resulting in unwanted side
products. There were a few errors that were encountered throughout the synthesis of these
reactions. A second approach was taken to determine which would give more optimal results.
For the second approach, the substitution reaction was first conducted and then the esterification
reaction was done prior to the dehydration reaction. This was tested because the 2’,7’dichlorofluorescein complex forms dimers with the boronic acid so too much product was being
lost when the dehydration reaction was conducted prior to the esterification reaction. Due to
unforeseen challenged with funding, there has been a short pause on the project while we await
more materials but in the future, each reaction will be further analyzed through mass
spectrometry and boron nuclear magnetic resonance (NMR). Eventually, the carborane cage will
be functionalized with cancer cell receptors such as folic acid, glucose, or cancer receptor sites.
Also, further biological analysis will have to be conducted on all of the obtained molecules.
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